Navigation Links
Intensive kidney dialysis indicates better survival rates than conventional dialysis
Date:4/25/2012

LONDON, ON Patients suffering with end-stage renal disease could increase their survival chances by undergoing intensive dialysis at home rather than the conventional dialysis in clinics. A new study by Lawson Health Research Institute shows the potential of more intensive dialysis completed in a home setting.

The study found that patients who underwent intensive dialysis at home have better survival rates than patients who had conventional dialysis in clinics. Intensive dialysis patients also had better blood pressure results and biochemical test values than conventional dialysis patients.

Dr. Gihad Nesrallah, a Lawson researcher, led the observational study comparing at home intensive dialysis and conventional dialysis in clinics. Intensive dialysis at home consists of eight hours of treatment, three to seven nights a week. Conventional dialysis that takes place in dialysis clinics is usually conducted in less than five hours, three days per week.

Dialysis providers and governments are recognizing the benefits of home based dialysis. The Ontario Renal Network has made independent, at home dialysis a priority for funding more frequent or longer term dialysis therapy. More observational studies, such as this one are needed to further investigate why intensive dialysis at home is more beneficial to the survival of patients.

"Strategies to improve survival for persons with end-stage renal disease are needed, and more intensive dialysis represents one of the more promising options that had emerged in the last two decades. We think that patients may wish to seriously consider intensive hemodialysis where possible," said Dr. Nesrallah.

This study, along with other observational studies focusing on kidney dialysis treatment, has the potential to influence policies centered around funding and gaining more resources to help make intensive at home kidney dialysis more readily available.


'/>"/>
Contact: Susan Mutterback
Susan.Mutterback@lhsc.on.ca
519-685-8500 x75664
Lawson Health Research Institute
Source:Eurekalert

Page: 1

Related biology news :

1. New study suggests EU biofuels are as carbon intensive as petrol
2. Everest expedition suggests nitric oxide benefits for intensive care patients
3. Calorific controversy for intensive care patients
4. Children with autism benefit from early, intensive therapy
5. Type 2 diabetes: Intensive versus conventional blood glucose control -- no clear picture
6. Researchers working toward automating sedation in intensive care units
7. Breema Center to Host International Intensive Week in Buhl, Germany
8. Intensive land management leaves Europe without carbon sinks
9. CU-Boulder study shows Maya intensively cultivated manioc 1,400 years ago
10. Harnessing cloud computing for data-intensive research on oceans, galaxies
11. Kidney stone mystery solved
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2015)... YORK , June 24, 2015 The ... rate. The major drivers for the market include growth ... number of new drug launches. Over the years, the ... increased. Between 2001 and 2010, the FDA approved 225 ... according to WIPO, Europe accounted ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, ... and authentication solutions, today announced enhanced functionality of ... authentication solution.  The enhancements build on the ... the DigitalPersona Altus platform and provide expanded ... In today,s environment of increasing ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
... 20 August 2010 - Pharma-Nutrition, the new international ... of scientific, technical and medical information products and ... and practical applications of medical nutrition in patient ... is set to take place next 18-20 April ...
... CHAPEL HILL Researchers at the University of North Carolina ... architecture controlling the growth of the collateral circulation the ... in the event of a heart attack or stroke. ... what are called collaterogenic therapies drugs or procedures that ...
... Four" Sherlock Holmes tells Watson he has written a monograph ... plates illustrating the difference in the ash." He finds the ... smoke during the commission of a crime. But Sherlock ... a patch on geologists and the "redox proxies" from which ...
Cached Biology News:Genetics underlie formation of body's back-up bypass vessels 2Geologists revisit the Great Oxygenation Event 2Geologists revisit the Great Oxygenation Event 3Geologists revisit the Great Oxygenation Event 4Geologists revisit the Great Oxygenation Event 5Geologists revisit the Great Oxygenation Event 6
(Date:7/1/2015)... July 1, 2015  Axovant Sciences Ltd. (NYSE: ... the treatment of dementia, today announced that the ... 22 at 5:45 p.m. EDT following its presentation ... International Conference 2015 (AAIC). The ... , Dr. Lawrence Friedhoff , Chief Development ...
(Date:7/1/2015)... ... 01, 2015 , ... A newly launched business plan contest will ask startup ... innovation in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see ... a period of expert mentorship from a senior industry figure drawn from the Pistoia ...
(Date:7/1/2015)... ... 01, 2015 , ... Apex Therapeutics announced today that company CEO, David Broecker ... , The presentation took place on Tuesday, June 16 and provided an update ... APX3330 for the treatment of pancreatic cancer. A copy of the company overview ...
(Date:7/1/2015)... July 1, 2015  UCB, a multinational biopharmaceutical ... global leader in designing, transforming, and running intelligent ... in recognition of their close collaboration in driving ... global business services (GBS) finance organization. ... clients that work together effectively to embrace the ...
Breaking Biology Technology:Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5
... (NASDAQ: AMGN ) today announced the submission of ... and Drug Administration (FDA) to expand the indication for XGEVA® ... the risk of developing bone metastases. If approved, XGEVA would ... spread of cancer to the bone. The ...
... June 27, 2011 Generex Biotechnology Corporation (OTCBB: GNBT) ... arising out of a blog post on Friday, June ... the Company,s common stock fell more than 20% and ... (Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b) The author of the blog ...
... Md., June 27, 2011 PharmAthene, Inc. (NYSE Amex: ... achieved an important technical milestone in its recombinant protective ... initial technology transfer of its manufacturing process for the ... the 100 liter scale to a US-based manufacturing facility ...
Cached Biology Technology:Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 2Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 3Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 4Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 5Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 6Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 7Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 8Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone 9Generex Provides Clarification of Facts 2Generex Provides Clarification of Facts 3Generex Provides Clarification of Facts 4Generex Provides Clarification of Facts 5PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer 2PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer 3
Bovine Serum...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
2.0 GHz Compaq Computer with 512 MB RAM, 32 MB AGP Graphics Card, 40 GB Hard Drive, 1 Serial Port & Open PCI Slot, Windows 2000 OS, MS Office, CD Read/Writer and 18 Flat Panel Monitor...
Quartz-Halogen, 100 W, High Intensity...
Biology Products: